Cann Group

Established in 2014, Cann Group Limited operates as a vertically integrated entity in the Australian medicinal cannabis sector, focusing on the breeding, cultivation, manufacturing, and supply of cannabis products. The company was a pioneer in the industry, becoming the first in Australia to secure a medicinal cannabis cultivation license in March 2017, followed by a research license. This foundational licensing enabled Cann Group to establish its leadership in plant genetics, breeding, and production techniques. The company went public on the Australian Securities Exchange (ASX:CAN) in May 2017, raising $13.5 million in its initial public offering.

The business model is centered on supplying high-quality medicinal cannabis for various medical conditions to patients within Australia and in approved export markets. Revenue is generated from the sale of its products, which include a range of dried flower and oil formulations, as well as active pharmaceutical ingredients (APIs). For the 2023 fiscal year, the company reported revenue from sales of $13.78 million. Cann Group serves prescribing clinicians and their patients, who can access the products through the Therapeutic Goods Administration's (TGA) Special Access and Authorised Prescriber schemes. The company has also established key supply agreements with distributors like Symbion, which services thousands of pharmacies and hospitals across Australia.

Cann Group's operations are supported by significant infrastructure, including research and manufacturing facilities in Bundoora, Melbourne, and a large-scale, state-of-the-art cultivation and GMP manufacturing facility near Mildura, Victoria. The Mildura facility has an initial capacity to produce 12,500kg of dry flower annually. The company's product portfolio includes its Botanitech brand and the proprietary Satipharm delivery system, which consists of patent-protected cannabinoid capsules. Collaborations with research partners like La Trobe University, Agriculture Victoria, and the CSIRO underpin its R&D efforts to develop specific genetic strains tailored for therapeutic effectiveness.

Peter Crock, who has a 28-year background in agribusiness with Nufarm, led the company as CEO from 2016 through its IPO and initial growth phase, stepping down in late 2022. Jenni Pilcher, an executive with extensive experience in the biotechnology and medical sectors, currently leads the company as Managing Director and CEO.

Keywords: medicinal cannabis Australia, Cann Group, cannabis cultivation, cannabis research, GMP manufacturing, phytopharmaceuticals, cannabis oil products, dried flower cannabis, Satipharm, Botanitech, plant genetics, cannabis breeding, ASX:CAN, therapeutic cannabis, Australian cannabis industry, cannabinoid science, pharmaceutical cannabis, Bundoora facility, Mildura facility, cannabis export